Pfizer Secures $10 Billion Metsera Acquisition, Outbidding Novo Nordisk in Obesity Drug Race
Table of Contents
Pfizer has reached an agreement to acquire obesity drug developer Metsera for $10 billion, ending a competitive bidding war with Danish pharmaceutical giant Novo Nordisk. The deal, finalized late Friday, positions Pfizer for significant growth in the burgeoning market for weight-loss treatments, despite Metsera’s therapies still being years away from potential approval.
Novo Nordisk Cites Antitrust Concerns, Withdraws Bid
Novo Nordisk confirmed its withdrawal from the acquisition process on Saturday, stating that the potential price and associated antitrust risks were deemed too high. The company had previously submitted bids reaching approximately $10 billion, including revised offers with increased cash payouts and reduced performance bonuses. However, Metsera ultimately favored Pfizer’s counteroffer after receiving a letter from the U.S. Federal Trade Commission (FTC) raising concerns about potential antitrust violations.
“Following a competitive process and after careful consideration, Novo Nordisk will not increase its offer to acquire Metsera, consistent with its commitment to financial discipline and shareholder value,” a company release stated. Novo Nordisk intends to continue pursuing other business development and acquisition opportunities.
FTC Scrutiny Played a Key Role
Metsera’s board determined that Novo Nordisk’s proposal carried “unacceptably high legal and regulatory risks” in comparison to the proposed merger with Pfizer. The FTC’s warning letter, delivered earlier in the week, highlighted potential antitrust issues that could have complicated Novo Nordisk’s acquisition.
Pfizer expressed its satisfaction with the revised agreement and anticipates closing the merger shortly after Metsera’s shareholder meeting on November 13, according to Reuters.
Implications for the Obesity Drug Market
This acquisition provides Pfizer with a crucial foothold in the rapidly expanding obesity drug market, currently dominated by Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly. While Metsera’s treatments are still in development, the potential for future revenue is substantial.
However, one analyst noted that the $10 billion price tag relies on optimistic projections, estimating Pfizer will need to generate approximately $11 billion in revenue from the deal by 2040 – nearly double Metsera’s current revenue forecasts. Growing skepticism surrounding the long-term pricing of GLP-1 medications, a class of drugs used for weight loss, could also impact potential profit margins.
Financial Outlook for Metsera and Pfizer
Metsera currently operates at a loss and is expected to continue incurring losses as its drug pipeline progresses through clinical trials. Despite this, Metsera’s board has recommended that shareholders approve the amended Pfizer offer. The acquisition underscores the increasing investment and competition within the pharmaceutical industry to address the global obesity epidemic.
Reuters contributed to this report.
